nach oben

Erschienen in:

19.08.2019 | Original Article

Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration

verfasst von: Ourania S. Kotsiou, Rajesh M. Jagirdar, Eleftherios D. Papazoglou, Chrissi Hatzoglou, Konstantinos I. Gourgoulianis, Sotirios G. Zarogiannis

Erschienen in: Inflammation | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Interleukin 33 (IL-33) is an alarmin with multiple roles in immunity and cell homeostasis, highly expressed in barrier sites, acting via the suppression of tumorigenicity 2 receptor (ST2). Production of IL-33 and soluble ST2 (sST2), a decoy receptor for IL-33, has been implicated in several pulmonary diseases, but both have been scarcely investigated in pleural diseases. The aim of this study was to determine the levels of IL-33 and sST2 in transudative (TrPEs), malignant (MPEs), and parapneumonic (PPEs) pleural effusions (PEs) and investigate the effect of PE fluids from each group with low and high IL-33/sST2 levels on MeT-5A cell adhesion and migration. IL-33 and sST2 pleural fluid levels were similar among TrPEs, MPEs, and PPEs. However, a significant correlation was found between IL-33 and LDH and in sST2 levels with lymphocyte counts in TrPEs. Additionally, in MPEs the levels of IL-33 correlated with the levels of sST2 and with the red blood cell counts. Furthermore, incubation of MeT-5A cells with MPEs and PPEs bearing low or high levels of IL-33/sST2 yielded significant differential effects on MeT-5A cell adhesion and migration. In MPEs, high IL-33/sST2 levels led to increased adhesion and migration of MeT-5A cells, while in PPEs the effect was the opposite, while no effect in both cell phenotypes was determined for TrPEs. These results reveal a clinical context dependent effect of the IL-33/sST2 axis in PEs.

Chang, J., Y.F. Xia, M.Z. Zhang, and L.M. Zhang. 2016. IL-33 signaling in lung injury. Translational Perioperative Pain Medicine 1: 24–32.PubMed

Liew, F.Y., N.I. Pitman, and I.B. McInnes. 2010. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature Reviews Immunology 10: 103–110. https://doi.org/10.1038/nri2692.CrossRefPubMed

Martin, N.T., and M.U. Martin. 2016. Interleukin 33 is a guardian of barriers and a local alarmin. Nature Immunology 17: 122–131. https://doi.org/10.1038/ni.3370.CrossRefPubMed

Griesenauer, B., and S. Paczesny. 2017. ST2/IL33 axis in immune cells during inflammatory diseases. Frontiers in Immunology 8: 475. https://doi.org/10.3389/fimmu.2017.00475.CrossRefPubMedPubMedCentral

Bajwa, E.K., J.A. Volk, D.C. Christiani, R.S. Harris, M.A. Matthay, B.T. Thompson, J.L. Januzzi, and National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network. 2013. Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome. Critical Care Medicine 41: 2521–2531. https://doi.org/10.1097/CCM.0b013e3182978f91.CrossRefPubMed

Tajima, S., K. Oshikawa, S. Tominaga, and Y. Sugiyama. 2003. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124: 1206–1214.CrossRef

Tzeng, H.T., C.C. Su, C.P. Chang, W.W. Lai, W.C. Su, and Y.C. Wang. 2018. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype. International Journal of Cancer 143: 1753–1763. https://doi.org/10.1002/ijc.31569.CrossRefPubMed

Xia, J., J. Zhao, J. Shang, M. Li, Z. Zeng, J. Zhao, J. Wang, Y. Xu, and J. Xie. 2015. Increased IL-33 expression in chronic obstructive pulmonary disease. American Journal of Physiology Lung Cell Molecular Physiology 308: 619–627. https://doi.org/10.1152/ajplung.00305.2014.CrossRef

Zhao, J., and Y. Zhao. 2015. Interleukin-33 and its receptor in pulmonary inflammatory diseases. Critical Reviews in Immunology 35: 451–461. https://doi.org/10.1615/CritRevImmunol.2016015865.CrossRefPubMedPubMedCentral

10.

Lee, K.S., H.R. Kim, S. Kwak, K.H. Choi, J.H. Cho, Y.L. Lee, M.K. Lee, and S.D. Park. 2013. Association between elevated pleural interleukin-33 levels and tuberculous pleurisy. Annals of Laboratory Medicine 33: 45–51. https://doi.org/10.3343/alm.2013.33.1.45.CrossRefPubMed

11.

Li, D., Y. Shen, X. Fu, M. Li, T. Wang, and F. Wen. 2015. Combined detections of interleukin-33 and adenosine deaminase for diagnosis of tuberculous pleural effusion. International Journal of Clinical Experimental Pathology 8: 888–893.PubMed

12.

Xuan, W.X., J.C. Zhang, Q. Zhou, W.B. Yang, and L.J. Ma. 2014. IL-33 levels differentiate tuberculous pleurisy from malignant pleural effusions. Oncology Letters 8: 449–453. https://doi.org/10.3892/ol.2014.2109.CrossRefPubMedPubMedCentral

13.

Kwon, B.I., S. Hong, K. Shin, E.H. Choi, J.J. Hwang, and S.H. Lee. 2013. Innate type 2 immunity is associated with eosinophilic pleural effusion in primary spontaneous pneumothorax. American Journal of Respiratory and Critical Care Medicine 188: 577–585. https://doi.org/10.1164/rccm.201302-0295OC.CrossRefPubMed

14.

Oshikawa, K., K. Yanagisawa, S. Ohno, S. Tominaga, and Y. Sugiyama. 2002. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. American Journal Respiratory Critical Care Medicine 165: 1005–1009. https://doi.org/10.1164/ajrccm.165.7.2105109.CrossRef

15.

Genofre, E.H., F.S. Vargas, L. Antonagelo, L.R. Teixeira, M.A.C. Vaz, E. Marchi, and V.L. Capelozzi. 2005. Ultrastructural acute features of active remodeling after chemical pleurodesis induced by silver nitrate or talc. Lung 183: 197–207. https://doi.org/10.1007/s00408-004-2536-x.CrossRefPubMed

16.

Batra, H., and V.B. Antony. 2015. Pleural mesothelial cells in pleural and lung diseases. Journal of Thoracic Diseases 7: 964–980. https://doi.org/10.3978/j.issn.2072-1439.2015.02.19.CrossRef

17.

Chalubinski, M., K. Wojdan, E. Luczak, P. Gorzelak, M. Borowiec, A. Gajewski, K. Rudnicka, M. Chmiela, and M. Broncel. 2015. IL-33 and IL-4 impair barrier functions of human vascular endothelium via different mechanisms. Vascular Pharmacology 73: 57–63. https://doi.org/10.1016/j.vph.2015.07.012.CrossRefPubMed

18.

Batra, H., and V.B. Antony. 2014. The pleural mesothelium in development and disease. Frontiers in Physiology 5: 284. https://doi.org/10.3389/fphys.2014.00284.CrossRefPubMedPubMedCentral

19.

Gillibert-Duplantier, J., B. Duthey, V. Sisirak, D. Salaün, T. Gargi, O. Trédan, P. Finetti, F. Bertucci, D. Birnbaum, N. Bendriss-Vermare, and A. Badache. 2012. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene. 31: 3516–3524. https://doi.org/10.1038/onc.2011.525.CrossRefPubMed

20.

Millar, N.L., C. O’Donnell, I.B. McInnes, and E. Brint. 2017. Wounds that heal and wounds that don’t—the role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. Seminars in Cell Developmental Biology 61: 41–50. https://doi.org/10.1016/j.semcdb.2016.08.007.CrossRefPubMed

21.

Light, R.W., M.I. Macgregor, P.C. Luchsinger, and J.C. Ball Jr. 1972. Pleural effusions: the diagnostic separation of transudates and exudates. Annals of Internal Medicine 77: 507–513.CrossRef

22.

Tsilioni, I., A.S. Filippidis, T. Kerenidi, A.V. Budanov, S.G. Zarogiannis, and K.I. Gourgoulianis. 2016. Sestrin-2 is significantly increased in malignant pleural effusions due to lung cancer and is potentially secreted by pleural mesothelial cells. Clinical Biochemistry 49: 726–728. https://doi.org/10.1016/j.clinbiochem.2016.02.002.CrossRefPubMed

23.

Miller, A.M. 2011. Role of IL-33 in inflammation and disease. Journal of Inflammation (London) 8: 22. https://doi.org/10.1186/1476-9255-8-22.CrossRef

24.

Zarogiannis, S.G., I. Tsilioni, C. Hatzoglou, P.A. Molyvdas, and K.I. Gourgoulianis. 2013. Pleural fluid protein is inversely correlated with age in uncomplicated parapneumonic pleural effusions. Clinical Biochemistry 46: 378–380. https://doi.org/10.1016/j.clinbiochem.2012.11.024.CrossRefPubMed

25.

Arsenopoulou, Z.V., I. Taitzoglou, P.A. Molyvdas, K.I. Gourgoulianis, C. Hatzoglou, and S.G. Zarogiannis. 2017. Silver nanoparticles alter the permeability of sheep pleura and of sheep and human pleural mesothelial cell monolayers. Environmental Toxicology & Pharmacology 50: 212–215.CrossRef

26.

Jagirdar, R.M., E. Apostolidou, P.A. Molyvdas, K.I. Gourgoulianis, C. Hatzoglou, and S.G. Zarogiannis. 2016. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent. American Journal of Physiology Lung Cellular and Molecular Physiology 310: 489–495. https://doi.org/10.1152/ajplung.00410.2015.CrossRef

27.

Mbarik, M., W. Kaabachi, B. Henidi, F.H. Sassi, and K. Hamzaoui. 2016. Soluble ST2 and IL-33: potential markers of endometriosis in the Tunisian population. Immunological Letters 166: 1–5. https://doi.org/10.1016/j.imlet.2015.05.002.CrossRef

28.

Giannou, A.D., A. Marazioti, M. Spella, N.I. Kanellakis, H. Apostolopoulou, I. Psallidas, Z.M. Prijovich, M. Vreka, D.E. Zazara, I. Lillis, V. Papaleonidopoulos, C.A. Kairi, A.L. Patmanidi, I. Giopanou, N. Spiropoulou, V. Harokopos, V. Aidinis, D. Spyratos, S. Teliousi, H. Papadaki, S. Taraviras, L.A. Snyder, O. Eickelberg, D. Kardamakis, Y. Iwakura, T.B. Feyerabend, H.R. Rodewald, I. Kalomenidis, T.S. Blackwell, T. Agalioti, and G.T. Stathopopulos. 2015. Mast cells mediate malignant pleural effusion formation. Journal of Clinical Investigation. 125: 2317–2334. https://doi.org/10.1172/JCI79840.CrossRefPubMed

29.

Wei, J., J. Zhao, V. Schrott, Y. Zhang, M. Gladwin, G. Bullock, and Y. Zhao. 2015. Red blood cells store and release interleukin-33. Journal of Investigative Medicine 63: 806–810. https://doi.org/10.1097/JIM.0000000000000213.CrossRefPubMedPubMedCentral

30.

Porcel, J.M., and M. Vives. 2003. Etiology and pleural fluid characteristics of large and massive effusions. Chest 124: 978–983.CrossRef

31.

Atanackovic, D., Y. Cao, J.W. Kim, S. Brandl, I. Thom, C. Faltz, Y. Hildebrandt, K. Bartels, A. de Weerth, S. Hegewisch-Becker, D.K. Hossfeld, and C. Bokemeyer. 2008. The local cytokine and chemokine milieu within malignant effusions. Tumour Biology 29: 93–104. https://doi.org/10.1159/000135689.CrossRefPubMed

32.

Fafliora, E., C. Hatzoglou, K.I. Gourgoulianis, S.G. Zarogiannis. 2016. Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiological Reports 4: pii: e12978. https://doi.org/10.14814/phy2.12978.CrossRef

33.

Milosavljevic, M.Z., J.P. Jovanovic, N.N. Pejnovic, S.L. Mitrovic, N.N. Arsenijevic, B.J. Simovic Markovic, and M.L. Lukic. 2016. Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma. Oncotarget 7: 18106–18115. https://doi.org/10.18632/oncotarget.7635.CrossRefPubMedPubMedCentral

34.

Choi, Y.S., H.J. Choi, J.K. Min, B.J. Pyun, Y.S. Maeng, H. Park, J. Kim, Y.M. Kim, and Y.G. Kwon. 2009. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediatedendothelial nitric oxide production. Blood 114: 3117–3126. https://doi.org/10.1182/blood-2009-02-203372.CrossRefPubMed

35.

Mutsaers, S.E. 2004. The mesothelial cell. International Journal of Biochemistry and Cell Biology 36: 9–16.CrossRef

36.

Cheah, H.M., S.M. Lansley, J.F. Varano Della Vergiliana, A.L. Tan, R. Thomas, S.L. Leong, J. Creaney, and Y.C. Lee. 2017. Malignant pleural fluid from mesothelioma has potent biological activities. Respirology 22: 192–199. https://doi.org/10.1111/resp.12874.CrossRefPubMed

37.

Demyanets, S., V. Konya, S.P. Kastl, C. Kaun, S. Rauscher, A. Niessner, R. Pentz, S. Pfaffenberger, K. Rychli, C.E. Lemberger, R. de Martin, A. Heinemann, I. Huk, M. Gröger, G. Maurer, K. Huber, and J. Wojta. 2011. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arteriosclerosis Thrombosis Vascular Biology 31: 2080–2089. https://doi.org/10.1161/ATVBAHA.111.231431.CrossRef

38.

Choi, Y.S., J.A. Park, J. Kim, S.S. Rho, H. Park, Y.M. Kim, and Y.G. Kwon. 2012. Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochemical Biophysical Research Communications 421: 305–311. https://doi.org/10.1016/j.bbrc.2012.04.005.CrossRefPubMed

39.

Porcel, J.M. 2013. Pleural fluid biomarkers: beyond the Light criteria. Clinics in Chest Medicine 34: 27–37.CrossRef

40.

Serrels, B., N. McGivern, M. Canel, A. Byron, S.C. Johnson, H.J. McSorley, N. Quinn, D. Taggart, A. Von Kreigsheim, S.M. Anderton, A. Serrels, M.C. Frame. 2017. IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks. Science Signaling 10: 508. pii: eaan8355. https://doi.org/10.1126/scisignal.aan8355.CrossRef

41.

Oshio, T., M. Komine, H. Tsuda, S.I. Tominaga, H. Saito, S. Nakae, and M. Ohtsuki. 2017. Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. Journal of Dermatological Sciences 85: 106–114. https://doi.org/10.1016/j.jdermsci.2016.10.008.CrossRef

42.

Lee, J.S., E. Seppanen, J. Patel, M.P. Rodero, and K. Khosrotehrani. 2016. ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis. Experimental Dermatology 25: 71–74. https://doi.org/10.1111/exd.12833.CrossRefPubMed

43.

Sedhom, M.A., M. Pichery, J.R. Murdoch, B. Foligné, N. Ortega, S. Normand, K. Mertz, D. Sanmugalingam, L. Brault, T. Grandjean, E. Lefrancais, P.G. Fallon, V. Quesniaux, L. Peyrin-Biroulet, G. Cathomas, T. Junt, M. Chamaillard, J.P. Girard, and B. Ryffel. 2013. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62: 1714–1723. https://doi.org/10.1136/gutjnl-2011-301785.CrossRefPubMed

44.

Chen, S.F., S. Nieh, S.W. Jao, M.Z. Wu, C.L. Liu, Y.C. Chang, and Y.S. Lin. 2013. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. Journal of Pathology 231: 180–189. https://doi.org/10.1002/path.4226.CrossRefPubMed

45.

Fang, K.M., C.S. Yang, T.C. Lin, T.C. Chan, and S.F. Tzeng. 2014. Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro-Oncology 16: 552–566. https://doi.org/10.1093/neuonc/not234.CrossRefPubMed

46.

Liu, J., J.X. Shen, J.L. Hu, W.H. Huang, and G.J. Zhang. 2014. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Frontiers in Immunology 5: 141. https://doi.org/10.3389/fimmu.2014.00141.CrossRefPubMedPubMedCentral

47.

Yu, X.X., Z. Hu, X. Shen, L.Y. Dong, W.Z. Zhou, and W.H. Hu. 2015. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Digestive Diseases and Sciences 60: 1265–1272. https://doi.org/10.1007/s10620-014-3463-1.CrossRefPubMed

48.

Liu, X., L. Zhu, X. Lu, H. Bian, X. Wu, W. Yang, and Q. Qin. 2014. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochemical Biophysical Research Communications 453: 486–492. https://doi.org/10.1016/j.bbrc.2014.09.106.CrossRefPubMed

49.

Alves-Filho, J.C., F. Sônego, F.O. Souto, A. Freitas, W.A.Jr. Verri, M. Auxiliadora-Martins, A. Basile-Filho, A.N. McKenzie, D. Xu, F.Q. Cunha, and F.Y. Liew. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nature Medicine 16: 708–712. https://doi.org/10.1038/nm.2156.CrossRefPubMed

50.

Vavougios, G., T. Kerenidi, I. Tsilioni, S.G. Zarogiannis, and K.I. Gourgoulianis. 2015. Pleural effusion levels of DJ-1 are increased in elderly lung cancer patients with malignant pleural effusions. Redox Reports 20: 254–258. https://doi.org/10.1179/1351000215Y.0000000023.CrossRef

Titel: Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration
verfasst von: Ourania S. Kotsiou
Rajesh M. Jagirdar
Eleftherios D. Papazoglou
Chrissi Hatzoglou
Konstantinos I. Gourgoulianis
Sotirios G. Zarogiannis
Publikationsdatum: 19.08.2019
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 6/2019
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-019-01070-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Inhibition of Fibroblast Growth Factor Receptor by AZD4547 Protects Against Inflammation in Septic Mice

Characterization of Circular RNA and microRNA Profiles in Septic Myocardial Depression: a Lipopolysaccharide-Induced Rat Septic Shock Model

Characteristics of Changes in Inflammatory Cytokines as a Function of Hepatic Ischemia-Reperfusion Injury Stage in Mice

Upregulated MiR-9-5p Protects Against Inflammatory Response in Rats with Deep Vein Thrombosis via Inhibition of NF-κB p50

Emodin Attenuates Severe Acute Pancreatitis via Antioxidant and Anti-inflammatory Activity